Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Rubius Therapeutics stock | $15.49

Learn how to easily invest in Rubius Therapeutics stock.

Rubius Therapeutics Inc is a biotechnology business based in the US. Rubius Therapeutics shares (RUBY) are listed on the NASDAQ and all prices are listed in US Dollars. Rubius Therapeutics employs 248 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Rubius Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RUBY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Rubius Therapeutics stock price (NASDAQ: RUBY)

Use our graph to track the performance of RUBY stocks over time.

Rubius Therapeutics shares at a glance

Information last updated 2021-10-23.
Latest market close$15.49
52-week range$4.20 - $32.97
50-day moving average $18.27
200-day moving average $22.56
Wall St. target price$29.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.09

Buy Rubius Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Rubius Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rubius Therapeutics price performance over time

Historical closes compared with the close of $15.49 from 2021-10-25

1 week (2021-10-20) -3.07%
1 month (2021-09-27) -18.69%
3 months (2021-07-27) -25.10%
6 months (2021-04-27) -35.70%
1 year (2020-10-26) 239.69%
2 years (2019-10-25) 63.74%
3 years (2018-10-26) 17.1
5 years (2016-10-23) N/A

Rubius Therapeutics financials

Gross profit TTM $0
Return on assets TTM -28.82%
Return on equity TTM -74.07%
Profit margin 0%
Book value $2.94
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting Rubius Therapeutics shares

There are currently 7.4 million Rubius Therapeutics shares held short by investors – that's known as Rubius Therapeutics's "short interest". This figure is 0.6% up from 7.4 million last month.

There are a few different ways that this level of interest in shorting Rubius Therapeutics shares can be evaluated.

Rubius Therapeutics's "short interest ratio" (SIR)

Rubius Therapeutics's "short interest ratio" (SIR) is the quantity of Rubius Therapeutics shares currently shorted divided by the average quantity of Rubius Therapeutics shares traded daily (recently around 311930.83403538). Rubius Therapeutics's SIR currently stands at 23.74. In other words for every 100,000 Rubius Therapeutics shares traded daily on the market, roughly 23740 shares are currently held short.

However Rubius Therapeutics's short interest can also be evaluated against the total number of Rubius Therapeutics shares, or, against the total number of tradable Rubius Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rubius Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Rubius Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.2107% of the tradable shares (for every 100,000 tradable Rubius Therapeutics shares, roughly 211 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Rubius Therapeutics.

Find out more about how you can short Rubius Therapeutics stock.

Rubius Therapeutics share dividends

We're not expecting Rubius Therapeutics to pay a dividend over the next 12 months.

Rubius Therapeutics share price volatility

Over the last 12 months, Rubius Therapeutics's shares have ranged in value from as little as $4.2 up to $32.97. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rubius Therapeutics's is 2.5732. This would suggest that Rubius Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Rubius Therapeutics overview

Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Rubius Therapeutics is owned by insiders or institutions?
Currently 5.574% of Rubius Therapeutics shares are held by insiders and 101.455% by institutions.
How many people work for Rubius Therapeutics?
Latest data suggests 248 work at Rubius Therapeutics.
When does the fiscal year end for Rubius Therapeutics?
Rubius Therapeutics's fiscal year ends in December.
Where is Rubius Therapeutics based?
Rubius Therapeutics's address is: 399 Binney Street, Cambridge, MA, United States, 02139
What is Rubius Therapeutics's ISIN number?
Rubius Therapeutics's international securities identification number is: US78116T1034
What is Rubius Therapeutics's CUSIP number?
Rubius Therapeutics's Committee on Uniform Securities Identification Procedures number is: 78116T103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site